VKTX
Viking Therapeutics, Inc.
Biotechnology · Healthcare · United States
27.28
close · 2026-10-30
value
94
cheaper than peers94
quality
50
stronger fundamentals50
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -3.3% | 96 |
| earnings yield, 3 years ago | -3.3% | 94 |
| earnings yield, 1 year ago | -3.7% | 90 |
| cash flow yield, 3 years ago | -1.4% | 89 |
| cash flow yield, 2 years ago | -2.1% | 88 |
| cash flow yield, 1 year ago | -2.5% | 86 |
| cash flow yield, latest year | -8.0% | 68 |
| earnings yield, latest year | -11.7% | 65 |
| price to book | 5.91× | 24 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.0% | 72 |
| operating margin | 0.0% | 50 |
| return on equity | -88.9% | 30 |
3 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | -$230.8M |
| employees | 65 |
| first trade | 2015-04-28 |
| next earnings | 2026-10-28 |
| fundamentals updated | 2026-10-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -3.19 | -1.01 | -0.91 | -0.90 | not reported |
| free cash flow | -$278.7M | -$87.8M | -$73.4M | -$48.4M | not reported |
| net income | -$359.6M | -$110.0M | -$85.9M | -$68.9M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | $55,000 | $112,000 | not reported | -$42,000 | $7,000 |